John M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman
December 10 2018 - 5:00PM
Syneos Health™ (Nasdaq:SYNH), the only fully integrated
biopharmaceutical solutions organization, today announced that John
M. Dineen has been appointed to the Company’s Board of Directors
and named Chairman of the Board. Dineen succeeds Michael A. Bell
who will continue to assist the Company as a consultant through a
transition period.
“We’re delighted to welcome John, a seasoned leader with broad
expertise across the healthcare and technology sectors, to our
Board,” said Alistair Macdonald, Chief Executive Officer of Syneos
Health. “We believe his decades of experience at General
Electric (GE), including his most recent position as Chief
Executive Officer of GE Healthcare, will enable him to provide
valuable strategic guidance to both our Board and management teams
as we advance our unique Lab to Life value proposition.”
Dineen is an independent director and has more than 30 years of
healthcare, technology and international management experience.
While at the helm of the $18 billion GE Healthcare business, he was
at the forefront of shaping patient care by providing
transformational medical technologies and services around the
world. Previously, Dineen spent more than two decades in a variety
of global leadership positions within GE, including President and
Chief Executive Officer of GE Transportation, President of GE
Plastics, General Manager of GE’s Power Equipment business, and
General Manager of GE’s Appliances, Microwave and Air-Conditioning
businesses.
Since 2015, Dineen has served as an operating advisor of the
investment firm Clayton, Dubilier & Rice, LLC. He also
currently serves on the Board of Directors of Cognizant Technology
Solutions Corporation (Nasdaq:CTSH), a leading provider of
information technology, consulting, and business process services,
and Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), an oncology
research and development company focused on biomarker-defined
cancers. Dineen received Bachelor’s degrees in Biology and Computer
Science from the University of Vermont.
About Syneos Health Syneos Health (Nasdaq:SYNH)
is the only fully integrated biopharmaceutical solutions
organization. Our company, including a Contract Research
Organization (CRO) and Contract Commercial Organization (CCO), is
purpose-built to accelerate customer performance to address modern
market realities. Created through the merger of two industry
leading companies – INC Research and inVentiv Health – we bring
together more than 23,000 clinical and commercial minds with the
ability to support customers in more than 110 countries. Together
we share insights, use the latest technologies and apply advanced
business practices to speed our customers’ delivery of important
therapies to patients. To learn more about how we are
shortening the distance from lab to life® visit
syneoshealth.com.
Contacts
Investor Relations: Ronnie Speight Senior Vice
President, Investor Relations +1 919 745 2745
investor.relations@syneoshealth.com
Press/Media: Danielle DeForge Executive
Director, External Communications +1 202 210 5992
danielle.deforge@syneoshealth.com
Cognizant Technology Sol... (NASDAQ:CTSH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cognizant Technology Sol... (NASDAQ:CTSH)
Historical Stock Chart
From Sep 2023 to Sep 2024